Importantly, cell proliferation and MAP kinase signaling were inhibited in three melanoma cell lines with NRAS activating mutations, Mel-Juso, SK-Mel-30, and SK-Mel-2, where BRAFWT was variably insensitive to 17-AAG. This evidence concerns the gene NRAS and melanoma.